Spine BioPharma develops SB-01, a first-in-class intradiscal injection therapy targeting degenerative disc disease to provide pain relief and restore functionality. This non-surgical, non-opiate treatment aims to improve the quality of life for individuals suffering from chronic low back pain.
Funding
$58.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Degenerative disc disease causes chronic low back pain and functional disability, significantly impacting patients' quality of life. Current treatment options are often limited to pain management with opiates or invasive surgical procedures, neither of which address the underlying disease pathology.
Solution
Spine BioPharma is developing SB-01, a first-in-class, non-surgical intradiscal injection therapy designed to treat degenerative disc disease. SB-01 aims to provide pain relief, restore spinal function, and potentially slow or stop disease progression. The therapeutic is administered directly into the affected disc by a physician. By targeting the source of the pain and addressing the underlying degeneration, SB-01 offers a potential alternative to traditional pain management and surgical interventions.
Target Audience
The primary target audience includes individuals suffering from chronic low back pain caused by degenerative disc disease, as well as physicians specializing in pain management and spine care.
Features
- Intradiscal injection for targeted delivery to the degenerated disc
- Potential to alleviate pain associated with degenerative disc disease
- Designed to restore functionality and mobility in patients with chronic low back pain
- May slow or halt the progression of degenerative disc disease
- Non-surgical and non-opiate based therapeutic approach